- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00065572
Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)
January 25, 2011 updated by: AstraZeneca
The purpose of this study is to assess the biological activity of ZD6126 in subjects with newly diagnosed metastatic renal cell carcinoma (stage IV).
Study Overview
Status
Suspended
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States
- Research Site
-
-
Delaware
-
Newark, Delaware, United States
- Research Site
-
-
Florida
-
Tampa, Florida, United States
- Research Site
-
-
Illinois
-
Chicago, Illinois, United States
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, United States
- Research Site
-
-
Maryland
-
Baltimore, Maryland, United States
- Research Site
-
-
Missouri
-
St. Louis, Missouri, United States
- Research Site
-
-
New Hampshire
-
Lebanon, New Hampshire, United States
- Research Site
-
-
New Jersey
-
Hackensack, New Jersey, United States
- Research Site
-
-
New York
-
Bronx, New York, United States
- Research Site
-
Rochester, New York, United States
- Research Site
-
-
Ohio
-
Cleveland, Ohio, United States
- Research Site
-
-
Oregon
-
Portland, Oregon, United States
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, United States
- Research Site
-
-
Utah
-
Salt Lake City, Utah, United States
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Newly diagnosed metastatic renal cell carcinoma
- Suitable for nephrectomy
Exclusion Criteria:
- Prior chemotherapy, biological therapy or radiation therapy for renal cell carcinoma or within the last 3 years for any other cancer
- Significant cardiac event within 3 months of entry
- Any history of coronary angioplasty or history of myocardial infarction
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2003
Primary Completion (ANTICIPATED)
February 1, 2004
Study Completion (ANTICIPATED)
February 1, 2004
Study Registration Dates
First Submitted
July 28, 2003
First Submitted That Met QC Criteria
July 30, 2003
First Posted (ESTIMATE)
July 31, 2003
Study Record Updates
Last Update Posted (ESTIMATE)
January 26, 2011
Last Update Submitted That Met QC Criteria
January 25, 2011
Last Verified
January 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D2820C00018
- 6126IL/00018
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Neoplasms
-
St. Petersburg State Pavlov Medical UniversitySaint Petersburg State University, RussiaCompleted
-
Philips HealthcareWithdrawnKidney TumorsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedKidney TumorUnited States
-
Tianjin Medical University Second HospitalRecruiting
-
Tianjin Medical University Second HospitalRecruiting
-
Thomas MuellerUnknownKidney Neoplasms | Adult Polycystic Kidney Disease | Kidney DysfunctionSwitzerland
-
Intuitive SurgicalCompleted
-
Yale UniversityCompleted
-
Stanford UniversityNational Cancer Institute (NCI)WithdrawnProstate Cancer | Bladder Cancer | Kidney Tumor
-
Association of Urologic Oncology (AUO)IAG-N at German Cancer Association (Deutsche Krebsgesellschaft e. V.)Not yet recruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States